Patents by Inventor Chengzhi Zhang

Chengzhi Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclopropane Carboxamide Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
    Publication number: 20190367492
    Abstract: The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: December 19, 2018
    Publication date: December 5, 2019
    Inventors: Chengzhi ZHANG, Justin CHAKMA
  • NOVEL PHARMACEUTICAL FORMULATIONS
    Publication number: 20190328661
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Application
    Filed: July 12, 2019
    Publication date: October 31, 2019
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • NOVEL PHARMACEUTICAL FORMULATIONS
    Publication number: 20190133935
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders.
    Type: Application
    Filed: November 1, 2018
    Publication date: May 9, 2019
    Inventors: Andreas SOMMER, Chengzhi ZHANG, John CARTER, John ARTHUR, Margaret BRADBURY
  • METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS
    Publication number: 20190092719
    Abstract: The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.
    Type: Application
    Filed: November 30, 2018
    Publication date: March 28, 2019
    Inventor: Chengzhi Zhang
  • Formulations And Pharmacokinetics Of Deuterated Benzoquinoline Inhibitors Of Vesicular Monoamine Transporter 2
    Publication number: 20190083484
    Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.
    Type: Application
    Filed: October 17, 2018
    Publication date: March 21, 2019
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
  • AZETIDINE MODULATORS OF THE SPHINGOSINE 1-PHOSPHATE RECEPTOR
    Publication number: 20190047951
    Abstract: Described are deuterium-substituted azetidine compounds of Formula (I), which are modulators of sphingosine 1-phosphate receptor. Also described are pharmaceutical compositions comprising the deuterium-substituted azetidine compounds, and methods of use thereof.
    Type: Application
    Filed: January 3, 2017
    Publication date: February 14, 2019
    Inventors: Chengzhi ZHANG, Justin CHAKMA
  • Cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator
    Patent number: 10167278
    Abstract: The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Grant
    Filed: December 27, 2015
    Date of Patent: January 1, 2019
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Chengzhi Zhang, Justin Chakma
  • Pharmaceutical formulations
    Patent number: 10166183
    Abstract: The present invention relates to new extended release pharmaceutical compositions and methods of use thereof for the treatment of disorders. In certain embodiments, disclosed herein is an extended-release pharmaceutical formulation comprising, in a solid dosage form for oral delivery of between about 100 mg and about 1 g total weight: between about 2 and about 18% of an active ingredient; between about 70% and about 96% of one or more diluents; between about 1% and about 10% of a water-soluble binder and between about 0.5 and about 2% of a surfactant.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: January 1, 2019
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury
  • DEUTERATED CHLOROKYNURENINES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
    Publication number: 20180305298
    Abstract: Described are deuterated chlorokynurenines and compositions, and their application as pharmaceuticals for the treatment of disease. Methods of modulating N-methyl-D-aspartate (NMDA) receptor activity, methods of treating disorders, including neuropsychiatric disorders such as depression, epilepsy, schizophrenia, and Huntington's Disease, and use of said deuterated chlorokynurenines are also described.
    Type: Application
    Filed: September 8, 2016
    Publication date: October 25, 2018
    Inventors: Gregory R. OTT, Chengzhi ZHANG, Ralph LAUFER
  • SUBSTITUTED CYCLOHEXANONES
    Publication number: 20180289637
    Abstract: The present disclosure provides compounds of Formula I and/or Formula II, or pharmaceutically acceptable salts thereof: wherein D is deuterium and each deuterium has deuterium enrichment of no less than about 10%, compositions containing these compounds, and methods of using these compounds.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Inventors: Ralph Laufer, Chengzhi Zhang, Yi Wang
  • Continudihydroxyphenyl Neurotransmitter Compounds, Compositions And Methods
    Publication number: 20180280511
    Abstract: The present invention relates to new dihydoxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Inventors: David S. Goldstein, Courtney Holmes, Rudolf-Giesbert Alken, Frank Schneider, Chengzhi Zhang
  • CYCLOPROPANECARBOXAMIDE MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
    Publication number: 20180265501
    Abstract: The present invention relates to new cyclopropanecarboxamide modulators of cystic fibrosis transmembrane conductance regulator proteins, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: December 27, 2015
    Publication date: September 20, 2018
    Inventors: Chengzhi ZHANG, Justin CHAKMA
  • ANALOGS OF DEUTETRABENAZINE, THEIR PREPARATION AND USE
    Publication number: 20180263972
    Abstract: The disclosure is directed to deutetrabenazine analogs, compositions comprising same and methods of detecting same in compositions comprising deutetrabenazine.
    Type: Application
    Filed: March 15, 2018
    Publication date: September 20, 2018
    Inventors: Chengzhi Zhang, Jim Kerr
  • METHODS OF MANUFACTURING BENZOQUINOLINE COMPOUNDS
    Publication number: 20180230083
    Abstract: The present invention relates to new methods of manufacturing benzoquinoline inhibitors of vesicular monoamine transporter 2 (VMAT2), and intermediates thereof.
    Type: Application
    Filed: April 12, 2018
    Publication date: August 16, 2018
    Inventor: Chengzhi Zhang
  • BENZOQUINOLONE INHIBITORS OF VMAT2
    Publication number: 20180208592
    Abstract: The present invention relates to new benzoquinolone inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: September 28, 2017
    Publication date: July 26, 2018
    Inventors: Andreas Sommer, Chengzhi Zhang
  • Tetrahydrocarbazole Inhibitors Of SIRT1 Receptors
    Publication number: 20180127366
    Abstract: Described are deuterium-substituted tetrahydrocarbazole compounds of Formulae I, II, or III which are inhibitors of sirtuin 1 (SIRT1). Also described are pharmaceutical compositions comprising the deuterium-substituted tetrahydrocarbazole compounds, and methods of use thereof.
    Type: Application
    Filed: January 3, 2018
    Publication date: May 10, 2018
    Inventors: Chengzhi Zhang, Ralph Laufer
  • Deuterium-Substituted Pyridin- And Pyrimidin-2-yl-Methylamine Compounds
    Publication number: 20180079742
    Abstract: Described are deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds of structural Formula (I), which are agonists of 5-hydroxytryptamine receptors. Also described are pharmaceutical compositions comprising the deuterium-substituted pyridin- and pyrimidin-2-yl-methylamine compounds, and methods of use thereof.
    Type: Application
    Filed: September 20, 2017
    Publication date: March 22, 2018
    Inventor: Chengzhi ZHANG
  • Deuterium-Substituted Oxazepin Compounds
    Publication number: 20180064726
    Abstract: Described are deuterium-substituted oxazepin compounds of structural Formula I, which are inhibitors/blockers of the late sodium current. Also described are pharmaceutical compositions comprising the deuterium-substituted oxazepin compounds, and methods of use thereof.
    Type: Application
    Filed: September 7, 2017
    Publication date: March 8, 2018
    Inventors: Richard FISHER, Chengzhi ZHANG
  • DIMETHOXYPHENYL INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2
    Publication number: 20180036260
    Abstract: Described are dimethoxyphenyl inhibitors of VMAT2, pharmaceutical compositions thereof, and methods of use thereof.
    Type: Application
    Filed: February 17, 2016
    Publication date: February 8, 2018
    Inventor: Chengzhi ZHANG
  • Tetrahydrocarbazole inhibitors of SIRT1 receptors
    Patent number: 9884819
    Abstract: Described are deuterium-substituted tetrahydrocarbazole compounds of Formulae I, II, or III which are inhibitors of sirtuin 1 (SIRT1). Also described are pharmaceutical compositions comprising the deuterium-substituted tetrahydrocarbazole compounds, and methods of use thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: February 6, 2018
    Assignee: Auspex Pharmaceuticals, Inc.
    Inventors: Chengzhi Zhang, Ralph Laufer